IRI_1170x120_2-14-20

migraine

Novartis and Amgen announce FDA approval of Aimovig

Novartis and Amgen announce FDA approval of Aimovig

Basel, SWITZERLAND – Novartis announced that the U.S. Food and Drug Administration (FDA) has approved Aimovig (erenumab) for the preventive treatment of migraine in adults. Aimovig is a novel therapeutic approach as the first and only FDA-approved treatment specifically developed to prevent migraine by blocking the calcitonin gene-related peptide receptor (CGRP-R), which is believed to

FDA approves new preventive treatment for migraines

FDA approves new preventive treatment for migraines

WASHINGTON — The U.S. Food and Drug Administration (FDA) has approved Aimovig (erenumab-aooe) for the preventive treatment of migraine in adults. The treatment is given by once-monthly self-injections. Aimovig is the first FDA-approved preventive migraine treatment in a new class of drugs that work by blocking the activity of calcitonin gene-related peptide, a molecule that

Impax’s Zomig Nasal Spray OK’d as pediatric migraine treatment

Impax’s Zomig Nasal Spray OK’d as pediatric migraine treatment

HAYWARD, Calif. — Impax Specialty Pharma’s Zomig Nasal Spray has been approved by the Food and Drug Administration for use in children ages 12 and older for the acute treatment of migraine. Parent company Impax Laboratories Inc. said Tuesday that the product  is the first nasal-delivered prescription medicine approved for the treatment of acute migraine